On June 9, 2026, Cartesian Therapeutics, Inc. entered into a strategic licensing agreement with WestGene Biopharma Co. to advance the development of in vivo chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases. Cartesian Therapeutics, Inc. is a biotechnology company focused on developing novel cell and gene therapies.
